The AJMC® Infectious Disease compendium is a comprehensive resource for news and interviews about the viruses, bacteria, fungi, and parasites that create illness and outbreaks.
June 10th 2025
New research reveals mental health recovery post COVID-19 takes nearly 3 times longer than physical health, highlighting the need for targeted care strategies.
USPSTF Advises Against Routine Serologic Screening for Genital Herpes Infection
February 14th 2023The US Preventive Services Task Force (USPSTF) reaffirmed previous recommendations against routine serologic screening for genital herpes infection among asymptomatic adolescents and adults, including pregnant individuals.
Read More
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, discussed how the FDA’s approval of Rebyota for the prevention of recurrent Clostridioides difficile infection (CDI) may promote cost effective management of CDI for patients and health systems.
Watch
Bloodstream Infection Risk Associated With Race, SES Among Patients on Hemodialysis
February 7th 2023Data released in the CDC’s latest Morbidity and Mortality Weekly Report indicate that patients with end-stage kidney disease on hemodialysis who are Black, Hispanic/Latino, or of lower socioeconomic status (SES) are at greater risk of Staphylococcus aureus bloodstream infections, with Hispanic/Latino ethnicity cited as an independent risk factor.
Read More
HHS updated guidance for states using Medicaid managed care to manage nonmedical needs; anxieties surrounding new variants rise amidst underreported COVID-19 cases in China, which defended its counts; public health campaigns try new strategies to increase trust and promote immunizations.
Read More
The Chinese government warns of backlash for countries requiring COVID-19 testing of travelers from China; monoclonal antibody drugs show some promise against infectious diseases, but costs need to be lower; the role of FDA and Biogen in approving Alzheimer drug Aduhelm is detailed in a scathing Congressional committee report.
Read More
Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI
December 21st 2022Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Watch
ICYMI: Top Content From DDW 2022
December 16th 2022Several therapeutic innovations in the management of Clostridioides difficile infection recurrence, current evidence on the efficacy of weight loss procedures in reversing nonalcoholic fatty liver disease, and an interview the use of artificial intelligence were spotlighted at Digestive Disease Week (DDW) 2022.
Read More
DAA Therapy Linked With Improved Liver, Mortality Outcomes in Patients With Chronic Hepatitis C
December 12th 2022Use of direct-acting antiviral (DAA) treatment (without interferon) was shown to reduce liver and nonliver complications, as well as improve long-term overall survival among patients with chronic hepatitis C.
Read More
COVID-19 Mortality Risk More Than Doubled Among Homeless Patients
December 6th 2022A cross-sectional study showed that patients experiencing homelessness were at more than 2-fold greater age-adjusted mortality risk due to COVID-19 compared with the general population, with these increased risks observed across race/ethnicity and sex status.
Read More
Glucose-Lowering Drugs May Reduce Risk of COVID-19–Related Adverse Events in Patients With Diabetes
December 6th 2022Patients with diabetes who reported use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, or metformin prior to COVID-19 infection were associated with lower COVID-19–related adverse outcomes during hospitalization.
Read More
Gaps Remain in HPV Vaccine Coverage for Children Due to COVID-19 Pandemic
December 3rd 2022The monthly volume of human papillomavirus (HPV) vaccine doses administered have returned to the level observed prior to the COVID-19 pandemic among children in an integrated health care system in California, but HPV vaccine coverage remains lower compared with prepandemic levels.
Read More
FDA Approves First Fecal Transplant Therapy for Prevention of CDI Recurrence
December 1st 2022Ferring’s Rebyota, a novel first-in-class microbiota-based live biotherapeutic, has been approved by the FDA for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Read More
Nutrition Associated With Recurrent CDI Risk in Elderly Patients
November 23rd 2022Elderly Japanese patients with a high geriatric nutritional risk index (GNRI) were associated with significantly better Clostridioides difficile infection (CDI) relapse-free survival compared with those with low GNRI.
Read More
CDI-Related Mortality Risk Greater in Hospitalized Children With Cystic Fibrosis
November 11th 2022Pediatric patients who developed coexisting Clostridioides difficile infection (CDI) while hospitalized for cystic fibrosis exhibited greater mortality risk, length of stay, and cost compared with those without cooccuring CDI.
Read More
Phase 3 Study Shows Live Biotherapeutic Significantly Reduces CDI Recurrence
November 8th 2022A phase 3 study showed Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, to be safe and significantly reduce recurrence of Clostridioides difficile infection (CDI) after antibiotic treatment, with a sustained response achieved through 6 months.
Read More
A poster presented at the Academy of Managed Care Pharmacy Nexus 2022 showed that patients with recurrent Clostridioides difficile infection (rCDI), who had Medicare Advantage Part D coverage or were enrolled in a commercial health plan were associated with significantly greater health care resource utilization, including emergency department and inpatient visits, compared with those without rCDI.
Read More
FDA Rejects Bulevirtide for Hepatitis D, Compensated Liver Disease
November 1st 2022The FDA has issued a complete response letter to Gilead Sciences, indicating that it cannot approve the company’s first-in-class investigational entry-inhibitor, bulevirtide, for the treatment of chronic hepatitis D virus infection and compensated liver disease.
Read More
Updated Clinical Practice Guidelines for CDI Show Improved Outcomes, but Adherence Issues Remain
October 25th 2022Improved outcomes associated with fidaxomicin compared with vancomycin suggest benefits from its greater use in Medicare patients, although uptake remains low despite its recommended use.
Read More
Racial Disparities Shown for Influenza Hospitalizations, Vaccination Coverage
October 20th 2022CDC's latest Morbidity and Mortality Weekly Report showed that US adults of non-Hispanic Black, American Indian or Alaska Native, and Hispanic race/ethnicity exhibited significantly higher influenza hospitalization rates and lower vaccination coverage compared with White adults.
Read More
Hepatitis C Morbidity, Mortality Risk Reduced in Homeless Patients Through Supportive Housing
October 13th 2022Patients with hepatitis C virus infection and chronic homelessness who were placed into permanent supportive housing exhibited a significantly reduced risk of hospitalization and liver-related morbidity and mortality.
Read More
Optum and Change Healthcare have completed their merger initiated in 2021; efficacy of the Jynneos vaccine is in question after 90 of 7339 individuals contracted monkeypox after vaccination; the CDC will no longer maintain a list of country-by-country COVID-19 travel advisories.
Read More